Breaking News Instant updates and real-time market news.

PTI

Proteostasis

$4.35

0.11 (2.59%)

07:54
12/17/19
12/17
07:54
12/17/19
07:54

Proteostasis to host conference call

Management discusses the positive Phase 2 top line results from the Proprietary CFTR Modulator combinations in F508del Homozygous Cystic Fibrosis patients on a conference call to be held on December 17 at 8:30 am. Webcast Link

PTI Proteostasis
$4.35

0.11 (2.59%)

03/26/19
WBLR
03/26/19
UPGRADE
WBLR
Outperform
William Blair upgrades Vertex to Outperform after 'subpar' competitor data
William Blair analyst Y. Katherine Xu upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform on expectations the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. Proteostasis' triplet efficacy falls short of the high bar set by the Vertex triples, Xu tells investors in a research note. While Proteostasis is starting a Phase II study of the triplet that would include a higher PTI-808 dose and test a longer duration aiming to optimize response with data out around year-end 2019, the chance of it matching or exceeding Vertex triple efficacy is "very low," contends the analyst. With both Galapagos (GLPG)/AbbVie (ABB) and Proteostasis having shown "subpar data," Xu is upgrading Vertex shares to Outperform and raised her fair value estimate for the shares to $222 from $178. The analyst maintains her high probability of success of a Vertex triple combo reaching the cystic fibrosis market at 90% and ascribe peak sales of $10.2B, up from $8.9 billion previously.
05/09/19
PIPR
05/09/19
NO CHANGE
Target $5
PIPR
Overweight
Proteostasis price target lowered to $5 from $10 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target on Proteostasis to $5 after its Q1 results that disclosed the company's $105M cash position and also to reflect its recently reported disappointing Phase 1 TripleRx data in homozygous F508del CF patients. The analyst maintains his Overweight rating on the stock but also lowers his estimate for Proteostasis' proprietary TripleRx regimen in the U.S. at $128M vs. $293M prior view.
11/06/19
PIPR
11/06/19
NO CHANGE
Target $4
PIPR
Overweight
Piper says Proteostasis guiding to TripleRx CF data sooner than expected
Piper Jaffray analyst Edward Tenthoff noted that Proteostasis said has completed enrollment of the Phase 2 study of 60 f508del cystic fibrosis patients ahead of schedule and is now guiding to top-line data by year-end 2019, which is ahead of the prior expectation of the first quarter of 2020. If it generates positive data for the triple combo of amplifier PTI-428 with CFTR corrector PTI-801 and potentiator PTI-808, Proteostasis could initiate a Phase 3 trial next year, said Tenthoff, who keeps an Overweight rating and $4 price target on Proteostasis shares.
12/04/19
CANT
12/04/19
INITIATION
Target $8
CANT
Overweight
Proteostasis assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Kristen Kluska assumed coverage of Proteostasis Therapeutics (PTI) with an Overweight rating with a price target of $8, down from $14. The stock is now set up for success, Kluska tells investors in a research note. While direct comparisons to Vertex (VRTX) will still be made, Proteostasis' doublet and triplet could lead to "robust improvements," contends the analyst.

TODAY'S FREE FLY STORIES

ETN

Eaton

$95.70

0.87 (0.92%)

08:35
01/21/20
01/21
08:35
01/21/20
08:35
Recommendations
Eaton analyst commentary  »

Eaton price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Feb

SLB

Schlumberger

$38.38

-0.38 (-0.98%)

08:35
01/21/20
01/21
08:35
01/21/20
08:35
Recommendations
Schlumberger analyst commentary  »

Schlumberger highlighted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCOM

Points International

$15.20

(0.00%)

08:34
01/21/20
01/21
08:34
01/21/20
08:34
Hot Stocks
Points International sees FY19 gross profit $59.2M-$59.6M »

Sees adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTC

Toro Company

$83.10

-0.67 (-0.80%)

08:33
01/21/20
01/21
08:33
01/21/20
08:33
Hot Stocks
Toro Company to acquire Venture Products for $167.5M in cash »

Toro Company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMI

Owens & Minor

$5.52

-0.27 (-4.66%)

08:33
01/21/20
01/21
08:33
01/21/20
08:33
Upgrade
Owens & Minor rating change  »

Owens & Minor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMP

Magellan Midstream

$64.28

-0.72 (-1.11%)

08:33
01/21/20
01/21
08:33
01/21/20
08:33
Hot Stocks
Magellan Midstream announces $750M common unit repurchase program »

The partnership announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

PCOM

Points International

$15.20

(0.00%)

08:33
01/21/20
01/21
08:33
01/21/20
08:33
Hot Stocks
Points International sees Q4 gross profit $17.3M-$17.7M »

Sees adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMP

Magellan Midstream

$64.28

-0.72 (-1.11%)

08:31
01/21/20
01/21
08:31
01/21/20
08:31
Hot Stocks
Magellan Midstream to sell marine terminals to Buckeye Partners for $250M »

Magellan Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

SINO

Sino-Global

$0.46

-0.0181 (-3.80%)

08:31
01/21/20
01/21
08:31
01/21/20
08:31
Hot Stocks
Sino-Global signs joint venture agreement with expert importer Shanming Liang »

Sino-Global Shipping…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVOK

Evoke Pharma

$1.58

-0.01 (-0.63%)

08:31
01/21/20
01/21
08:31
01/21/20
08:31
Hot Stocks
Evoke Pharma announces FDA acceptance of NDA resubmission for Gimoti »

Evoke Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DL

China Distance Education

$9.06

0.085 (0.95%)

, FRAN

Francesca's

$9.20

-0.25 (-2.65%)

08:30
01/21/20
01/21
08:30
01/21/20
08:30
Options
Twelve option delistings on January 21st »

Option delistings…

DL

China Distance Education

$9.06

0.085 (0.95%)

FRAN

Francesca's

$9.20

-0.25 (-2.65%)

HMNY

Helios and Matheson

$0.00

(0.00%)

LIFE

aTyr Pharma

$6.24

-0.785 (-11.18%)

NIHD

NII Holdings

$0.00

(0.00%)

NVLNF

Novelion Therapeutics

$0.00

(0.00%)

SES

Synthesis Energy Systems

$6.96

-0.18 (-2.52%)

SMTA

Spirit MTA REIT

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTGN

Neon Therapeutics

$1.70

0.01 (0.59%)

08:28
01/21/20
01/21
08:28
01/21/20
08:28
Upgrade
Neon Therapeutics rating change  »

Neon Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

$166.57

4.77 (2.95%)

08:27
01/21/20
01/21
08:27
01/21/20
08:27
Recommendations
Kansas City Southern analyst commentary  »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:25
01/21/20
01/21
08:25
01/21/20
08:25
Conference/Events
JPMorgan retail analyst to hold an analyst/industry conference call »

Retailing Analyst…

EVSI

Envision Solar

$6.48

0.46 (7.64%)

08:23
01/21/20
01/21
08:23
01/21/20
08:23
Hot Stocks
Envision Solar announces further orders through State of California contract »

Envision Solar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEMP

Hemp, Inc.

$0.00

(0.00%)

08:21
01/21/20
01/21
08:21
01/21/20
08:21
Hot Stocks
Hemp, Inc. supports House legislation that promotes CBD as dietary supplement »

Hemp, Inc. announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

SHAK

Shake Shack

$69.92

-0.495 (-0.70%)

08:20
01/21/20
01/21
08:20
01/21/20
08:20
Recommendations
Shake Shack analyst commentary  »

Shake Shack price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KERN

Akerna

$8.70

0.06 (0.69%)

08:19
01/21/20
01/21
08:19
01/21/20
08:19
Hot Stocks
Akerna completes acquisition of majority interest in solo sciences »

Akerna has completed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

RF

Regions Financial

$16.36

-0.31 (-1.86%)

08:19
01/21/20
01/21
08:19
01/21/20
08:19
Upgrade
Regions Financial rating change  »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 17

    Apr

PETS

PetMed Express

$27.28

0.76 (2.87%)

08:17
01/21/20
01/21
08:17
01/21/20
08:17
Earnings
PetMed Express reports Q3 EPS 34c, two est. 30c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

UBER

Uber

$35.12

0.45 (1.30%)

08:16
01/21/20
01/21
08:16
01/21/20
08:16
Recommendations
Uber analyst commentary  »

Uber's sale of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

OTGLY

CD Projekt

$0.00

(0.00%)

08:15
01/21/20
01/21
08:15
01/21/20
08:15
Downgrade
CD Projekt rating change  »

CD Projekt downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENPH

Enphase Energy

$31.49

0.65 (2.11%)

08:15
01/21/20
01/21
08:15
01/21/20
08:15
Hot Stocks
Enphase Energy, Petersen-Dean partner for solar, storage solutions for new homes »

Enphase Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWKH

SWK Holdings

$0.00

(0.00%)

08:14
01/21/20
01/21
08:14
01/21/20
08:14
Hot Stocks
SWK Holdings approved for listing on Nasdaq »

SWK Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCYT

H-CYTE

$0.00

(0.00%)

08:14
01/21/20
01/21
08:14
01/21/20
08:14
Hot Stocks
H-CYTE expects to achieve cashflow breakeven 'as early as this year' »

H-CYTE issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.